Welcome to the international HTA database

Showing [24117 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2005	Agency for Healthcare Research and Quality (AHRQ)	Perinatal depression: prevalence, screening accuracy, and screening outcomes
2007	Adelaide Health Technology Assessment (AHTA)	Perinatal Hepatitis C screening
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Periodic dental examinations for oral health: a review of clinical effectiveness, cost effectiveness, and guidelines
2013	Health Quality Ontario (HQO)	Periodic health examinations: a rapid economic analysis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Periodontal regenerative procedures for patients with periodontal disease: a review of clinical effectiveness
2006	Haute Autorite de sante (HAS)	Perioperative blood salvage
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Perioperative chemotherapy for operable gastro-oesophageal cancer - horizon scanning review
2022	NIHR Health Services and Delivery Research programme	Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Periostat for periodontal disease: a review of the clinical effectiveness, cost effectiveness and guidelines
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Peripartum or postnatal care disparities and equity
1997	University HealthSystem Consortium (UHC)	Peripheral blood progenitor cell transplantation
2017	HAYES, Inc.	Peripheral nerve ablation for treatment of osteoarthritic knee pain
2014	Health Quality Ontario (HQO)	Peripheral nerve blocks for post-operative pain relief after arthroscopic knee ligament reconstruction: a rapid review
2006	HAYES, Inc.	Peripheral nerve decompression for diabetic neuropathy
2024	Ontario Health	Peripheral nerve stimulation for chronic neuropathic pain
2024	Ontario Health	Peripheral nerve stimulation for chronic neuropathic pain: a health technology assessment
2013	National Institute for Health and Care Excellence (NICE)	Peripheral nerve-field stimulation for chronic low back pain. NICE interventional procedures guidance 451
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peripherally inserted central catheter-associated mast cell activation syndrome: clinical evidence
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peripherally Inserted Central Catheters (PICCs) for adult and pediatric patients: a review of clinical evidence
2016	HAYES, Inc.	Peristeen anal irrigation system (Coloplast) for bowel management in pediatric populations
2018	National Institute for Health and Care Excellence (NICE)	Peristeen Plus transanal irrigation system for managing bowel dysfunction. NICE medical technologies guidance 36
2006	Medical Services Advisory Committee (MSAC)	Peritonectomy (nationally funded centres)
2012	National Institute for Health and Care Excellence (NICE)	PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. NICE medical technologies guidance 9
2010	Penn Medicine Center for Evidence-based Practice (CEP)	Permacol implants for hernia repair
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity
2009	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Permanent and semi permanent dermal fillers
2021	National Institute for Health and Care Excellence (NICE)	Permanent His-bundle pacemaker implantation for treating heart failure. NICE interventional procedures guidance 694
2025	Health Technology Wales (HTW)	Permanent implant brachytherapy devices for the treatment of locally advanced, unresectable pancreatic cancer
1999	ECRI	Permanent prostate brachytherapy for localized prostate cancer
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Permaseal for soft tissue access and closure during procedures
2015	HAYES, Inc.	Peroral Endoscopic Myotomy (POEM) for treatment of esophageal achalasia
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Personal protection for visitors to patients on airborne precautions: clinical effectiveness and guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Personal protection for visitors to patients on airborne precautions: clinical effectiveness and guidelines
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Personal protective equipment and evidence-based advice for surgical departments during COVID-19
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Personal protective equipment for antibiotic resistant organisms in rehabilitation facilities: clinical evidence and guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Personal wireless device use for wound care consultation: a review of safety, clinical benefits and guidelines
2022	National Institute for Health and Care Excellence (NICE)	Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. NICE interventional procedures guidance 724
2019	Health Quality Ontario (HQO)	Perspectives of Pregnant People and Clinicians on Noninvasive Prenatal Testing: A Systematic Review and Qualitative Meta-synthesis
2012	Health Council of the Netherlands Gezondheidsraad (GR)	Perspectives on oral health care
1997	Health Council of the Netherlands Gezondheidsraad (GR)	Pertussis: a critical appraisal
2000	Health Council of the Netherlands Gezondheidsraad (GR)	Pertussis: a critical appraisal (2)
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) for HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab and docetaxel
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy
2019	National Institute for Health and Care Excellence (NICE)	Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. NICE technology appraisal guidance 569
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab for metastatic HER2-positive gastric cancer – first line
2016	National Institute for Health and Care Excellence (NICE)	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer. NICE technology appraisal guidance 424
2013	NIHR Health Technology Assessment programme	Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer: a single technology appraisal
2018	National Institute for Health and Care Excellence (NICE)	Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer. NICE technology appraisal guidance 509
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Pesky gNATs cognitive behaviour therapy for children with anxiety and low mood
2002	ECRI	PET for diagnosis of Alzheimer's disease
1997	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	PET in non-neurological clinical oncology. IPE-97/11 (Public report)
2001	Institute for Clinical Systems Improvement (ICSI)	PET scans for solitary pulmonary nodules, non-small cell lung cancer, recurrent colorectal cancer, lymphoma, and recurrent melanoma
2019	Andalusian Health Technology Assessment Area (AETSA)	PET usefulness in non-oncological indications
2004	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	PET-CT: indications, systematic review and meta-analysis IPE-04/41 (Public report)
2017	NIHR Health Technology Assessment programme	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer
2017	NIHR Health Technology Assessment programme	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer
2018	NIHR Health Technology Assessment programme	PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
2025	Institute of Health Economics (IHE)	PET/CT capacity for cancer diagnosis and follow-up: rapid review
2013	Scottish Health Technologies Group (SHTG)	PET/CT for the inversitgation of paraneoplastic syndromes (PNS)
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	PET/PET-CT Evidence for need based planning in Germany and Austria
2010	HAYES, Inc.	Peutz-Jeghers Syndrome (PJS)
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pexiganan (Locilex) for mild foot infection in diabetic foot ulcers
2008	HAYES, Inc.	PGxPredic: Rituximab Test (PGxHealth) for FCGR3A variants in follicular CD20-positive non-Hodgkin's Lymphoma
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Phagenyx™ for stroke-induced dysphagia
2002	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Phakic intraocular lens implantation - systematic review, expert panel
2009	Medical Advisory Secretariat (MAS)	Phakic intraocular lenses for the treatment of low to high refractive errors: an evidence-based analysis
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Phallometric assessment of sex offenders: a review of the clinical evidence and guidelines
1996	Alberta Heritage Foundation for Medical Research (AHFMR)	Phalloplasty in female-male transsexuals
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015
2009	Belgian Health Care Knowledge Centre (KCE)	Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment
2009	Belgian Health Care Knowledge Centre (KCE)	Pharmaceutical and nonpharmaceutical interventions for Alzheimer’s disease, a rapid assessment
2018	Adelaide Health Technology Assessment (AHTA)	Pharmaceutical Benefits Scheme post-market review of Pulmonary Arterial Hypertension medicines
1996	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Pharmaceutical management of gastroesophageal reflux disease - summary
1996	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Pharmaceutical management of peptic ulcer disease
2000	Israel Center for Technology Assessment in Health Care (ICTAHC)	Pharmaceutical services in Israeli hospitals - a national survey
1997	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Pharmacoeconomic evaluation in schizophrenia: clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia
1997	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia - summary
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2019	Health Technology Wales (HTW)	Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications
2009	Blue Cross Blue Shield Association (BCBS)	Pharmacogenetic testing to predict serious toxicity from 5-Fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer
2000	Health Council of the Netherlands Gezondheidsraad (GR)	Pharmacogenetics
2008	VA Technology Assessment Program (VATAP)	Pharmacogenomic testing
2017	Health Quality Ontario (HQO)	Pharmacogenomic testing for psychotropic medication selection: a systematic review of the Assurex GeneSight Psychotropic test
2007	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacogenomics and warfarin therapy
2008	Blue Cross Blue Shield Association (BCBS)	Pharmacogenomics-based treatment of helicobacter pylori infection
2014	Agency for Healthcare Research and Quality (AHRQ)	Pharmacokinetic/pharmacodynamic measures for guiding antibiotic treatment for hospital acquired pneumonia
2012	HAYES, Inc.	Pharmacokinetically guided dose adjustment of 5-fluorouracil (5-FU)
2013	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and mechanical prophylaxis of venous thromboembolism among special populations
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacologic and non-pharmacologic treatments for alcohol withdrawal in the outpatient setting: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2019	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and nonpharmacologic therapies in adult patients with exacerbation of COPD